Suppression of IRF4 by IRF1, 3, and 7 in Noxa expression is a necessary event for IFN-γ-mediated tumor elimination

Molecular Cancer Research

Volumn 9, Issue 10, 2011, Pages 1356-1365

  Piya, Sujan ^a,e   Moon, Ae Ran ^a   Song, Peter I ^b   Hiscott, John ^c   Lin, Rongtuan ^c   Seol, Dai Wu ^d   Kim, Tae Hyoung ^a  

^a Chosun University   (South Korea)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d Chung Ang University   (South Korea)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 4; INTERFERON REGULATORY FACTOR 7; LIPOPOLYSACCHARIDE; PROTEIN NOXA; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL DEATH; CHEMOSENSITIVITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; GENE SILENCING; HOMEOSTASIS; HUMAN; HUMAN CELL; INTERFERON INDUCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR ESCAPE; TUMOR REJECTION; UPREGULATION; WILD TYPE;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL DEATH; DISEASE MODELS, ANIMAL; HCT116 CELLS; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON REGULATORY FACTOR-3; INTERFERON REGULATORY FACTOR-7; INTERFERON REGULATORY FACTORS; INTERFERON-GAMMA; JURKAT CELLS; MALE; MICE; MICE, INBRED BALB C; PROTO-ONCOGENE PROTEINS C-BCL-2;

MUS;

EID: 80054698887     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-11-0185     Document Type: Article

References (37)

1. Burnet FM. An immunological approach to ageing. Lancet 1970;2:358-60.
2. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27.
3. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994;1:447-56.
4. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11. (Pubitemid 32391043)
5. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998;95:7556-61. (Pubitemid 28293291)
6. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000;192:755-60.
7. Enzler T, Gillessen S, Manis JP, Ferguson D, Fleming J, Alt FW, et al. Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med 2003;197:1213-9. (Pubitemid 36570077)
8. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001;7:94-100. (Pubitemid 32095647)
9. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000;191:661-8.
10. Street SE, Hayakawa Y, Zhan Y, Lew AM, MacGregor D, Jamieson AM, et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med 2004;199:879-84. (Pubitemid 38375207)
11. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002;196:129-34. (Pubitemid 34747318)
12. Fallarino F, Gajewski TF. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol 1999;163:4109-13. (Pubitemid 29474472)
13. Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, et al. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med 2003;198:433-42. (Pubitemid 36976054)
14. Caligiuri MA. Human natural killer cells. Blood 2008;112:461-9.
15. Elboim M, Gazit R, Gur C, Ghadially H, Betser-Cohen G, Mandelboim O. Tumor immunoediting by NKp46. J Immunol 2010;184:5637-44.
16. Lou Y, Vitalis TZ, Basha G, Cai B, Chen SS, Choi KB, et al. Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res 2005;65:7926-33. (Pubitemid 41297271)
17. Seliger B, Hohne A, Knuth A, Bernhard H, Ehring B, Tampe R, et al. Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin Cancer Res 1996;2:1427-33. (Pubitemid 26299444)
18. Dovhey SE, Ghosh NS, Wright KL. Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line. Cancer Res 2000;60:5789-96.
19. Jefferies WA, Kolaitis G, Gabathuler R. IFN-gamma-induced recognition of the antigen-processing variant CMT.64 by cytolytic T cells can be replaced by sequential addition of beta 2 microglobulin and antigenic peptides. J Immunol 1993;151:2974-85. (Pubitemid 23282610)
20. Goubau D, Romieu-Mourez R, Solis M, Hernandez E, Mesplede T, Lin R, et al. Transcriptional re-programming of primary macrophages reveals distinct apoptotic and anti-tumoral functions of IRF-3 and IRF-7. Eur J Immunol 2009;39:527-40.
21. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005;17:525-35. (Pubitemid 40269117)
22. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17:393-403. (Pubitemid 40193310)
23. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000;288:1053-8. (Pubitemid 30324238)
24. Sun Y, Leaman DW. Involvement of Noxa in cellular apoptotic responses to interferon, double-stranded RNA, and virus infection. J Biol Chem 2005;280:15561-8. (Pubitemid 40616672)
25. Porta C, Hadj-Slimane R, Nejmeddine M, Pampin M, Tovey MG, Espert L, et al. Interferons alpha and gamma induce p53-dependent and p53-independent apoptosis, respectively. Oncogene 2005;24:605-15. (Pubitemid 40188565)
26. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005;65:6282-93. (Pubitemid 40994414)
27. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006;107:257-64. (Pubitemid 43053550)
28. Tailor P, Tamura T, Ozato K. IRF family proteins and type I interferon induction in dendritic cells. Cell Res 2006;16:134-40. (Pubitemid 43247968)
29. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005;434:772-7. (Pubitemid 44739521)
30. Lehtonen A, Veckman V, Nikula T, Lahesmaa R, Kinnunen L, Matikainen S, et al. Differential expression of IFN regulatory factor 4 gene in human monocyte-derived dendritic cells and macrophages. J Immunol 2005;175:6570-9. (Pubitemid 41598899)
31. Lu R. Interferon regulatory factor 4 and 8 in B-cell development. Trends Immunol 2008;29:487-92.
32. Freudenberg MA, Tchaptchet S, Keck S, Fejer G, Huber M, Schutze N, et al. Lipopolysaccharide sensing an important factor in the innate immune response to Gram-negative bacterial infections: benefits and hazards of LPS hypersensitivity. Immunobiology 2008;213:193-203.
33. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in toll-like receptor signalling. Nat Rev Immunol 2007;7:353-64. (Pubitemid 46674493)
34. Lallemand C, Blanchard B, Palmieri M, Lebon P, May E, Tovey MG. Single-stranded RNA viruses inactivate the transcriptional activity of p53 but induce NOXA-dependent apoptosis via post-translational modifications of IRF-1, IRF-3 and CREB. Oncogene 2007;26:328-38. (Pubitemid 46122823)
35. Bai Y, Ahmad U, Wang Y, Li JH, Choy JC, Kim RW, et al. Interferongamma induces X-linked inhibitor of apoptosis-associated factor-1 and Noxa expression and potentiates human vascular smooth muscle cell apoptosis by STAT3 activation. J Biol Chem 2008;283:6832-42.
36. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, et al. IRF4 addiction in multiple myeloma. Nature 2008;454:226-31. (Pubitemid 351969894)
37. Gao J, Senthil M, Ren B, Yan J, Xing Q, Yu J, et al. IRF-1 transcriptionally upregulates PUMA, which mediates the mitochondrial apoptotic pathway in IRF-1-induced apoptosis in cancer cells. Cell Death Differ 2010;17:699-709.